WO1995003293A1 - Isoflavone derivatives - Google Patents
Isoflavone derivatives Download PDFInfo
- Publication number
- WO1995003293A1 WO1995003293A1 PCT/HU1994/000028 HU9400028W WO9503293A1 WO 1995003293 A1 WO1995003293 A1 WO 1995003293A1 HU 9400028 W HU9400028 W HU 9400028W WO 9503293 A1 WO9503293 A1 WO 9503293A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- general formula
- alkyl
- group
- compounds
- isoflavone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/38—2,3-Dihydro derivatives, e.g. isoflavanones
Definitions
- the present invention relates to isoflavone, isoflavan-4-one and isoflavane derivatives of the general formula (I),
- R 1 represents C ⁇ galkyl substituted by alkylcarbonyl, carboxy, sulfonic acid, hydroxy, phenoxy, piperidino, morpholino or piridino or by a
- R 1 represents C 1 -. 18 alkyl optionally substituted by alkyl-carbonyl, alkoxycarbonyl, carboxy, sulfonic acid, hydroxy, phenoxy, piperidino, morpholino or piridino or by a (C 1 _. 4 al yl) 2 N-(CH 2 ) m CO(CH 2 )p- group; or stands for C 3 .
- R 1 represents C ⁇ galkyl optionally substituted by alkyl-carbonyl, alkoxycarbonyl, carboxy, sulfonic acid, hydroxy, alkoxy, phenyl optionally substituted by a halo atom, phenoxy, piperidino, morpholino or piridino or by a (C 1 - 4 alkyl) 2 N-(CH 2 ) m CO(CH 2 )p- group; or stands for C 3 .
- R stands for C-*_ 8 alkyl, halogen, C ⁇ alkoxymethyl, C 2 . 5 -acyloxymethyl, or hydroxymethyl;
- R 4 stands for hydrogen or C ⁇ alkyl;
- R 2 and R 3 stand for hydrogen or C galkoxy
- R 5 and R 6 together stand for an oxo group or separately stand for hydrogen; the dotted line means a double bond being optionally present; n is 0 or 1; m is an integer from 1 to 4; and p is an integer from 1 to 4.
- the compounds of the general formula (I) can be used for the prevention and treatment of osteoporosis.
- the compounds of the general formula (IA) can be prepared by reacting ketones of the general formula
- R, n, R 1 , R 2 and R 3 are as defined for the general formula (I), a) with alkyl orthoformate in the presence of a basic catalyst, or b) with hydrogen cyanide and/or cyanic salts in the presence of hydrohalides; or c) with alkyl formiate in the presence of an alkali metal; or d) with alkyloxalylhalide, and the isoflavone ester thus obtained is, if desired, saponified and/or decarboxylated; or e) with organic carboxylic anhydride; or f) with N,N-dialkyl acid amide in the presence of phosphorous chloride; or g) by dehydrating 2-hydroxy-isoflavanone derivatives of the general formula (I), a) with alkyl orthoformate in the presence of a basic catalyst, or b) with hydrogen cyanide and/or cyanic salts in the presence of hydrohalides; or c) with alkyl formiate in the presence
- a suitably substituted ketone is reacted with alkyl orthoformiate, preferably ethyl ester, in an aprotic solvent having a high boiling point.
- a solvent pyrrolidine, dimethyl formamide or diethylene glycol dimethyl ether is used.
- a basic catalyst preferably " piperidine, morpholine, pyrrolidine and other secondary amines may be used.
- the ketones are reacted with hydrogen cyanide in an aprotic solvent in the presence of dry gaseous hydrochloric acid or other hydrohalogenic acids or Lewis acids.
- Non-basic aprotic solvents may also be used in the reaction, preferably diethyl ether or other dialkyl ethers.
- catalyst zinc chloride or other Lewis acids may be used.
- the reaction is carried out with hydrogen cyanide or an appropriate salt thereof, preferably with zinc cyanide.
- the mixture may be saturated with dry gaseous hydrochloric acid and the substituted ⁇ -fo ⁇ nimino-2-hydroxyphenylben2yl-ketone chlorohydrates thus obtained are decomposed with aqueous treatment.
- the ketones of the formula (IH) are reacted with alkyl formiates in the presence of an alkali metal.
- a 2-alkoxycarbonyl-isoflavone derivative is obtained, which is, if desired, converted into an isoflavone derivative unsubstituted in position 2 by hydrolyzing the ester group and by subsequent decarboxylation.
- This process variant can preferably be carried out with methyl- or ethyl oxalyl chloride in the presence of a basic acid binding agent in an appropriate aprotic solvent, preferably pyridine or another tertiary amine.
- the suitably substituted 2-hydroxy-phenyl benzyl ketone is reacted with organic acid anhydrides in the presence of a basic catalyst.
- a basic catalyst suitably an alkali salt of the acid component of the acid anhydride, or in the presence of tertiary amines, without solvent or in an aprotic solvent having high boiling point, such as pyridine or dimethyl formamide.
- the ketone is reacted with N,N-dialkyl acid amides in the presence of phosphorus oxychloride, preferably by heating the suitably substituted 2-hydroxy-phenyl benzyl ketone with N,N-dialkyl acid amid (e.g. dimethyl formamide or dimethyl acetamide) and phosphorous oxychloride, using as solvent the N,N-dialkyl acid amide itself.
- N,N-dialkyl acid amid e.g. dimethyl formamide or dimethyl acetamide
- phosphorous oxychloride e.g. dimethyl formamide or dimethyl acetamide
- 2-hydroxy-isoflavones of the formula (IV) are dehydrated by heating or by warming in an acidic medium in polar solvent.
- such derivatives may be obtained from the compounds of the formula (HI) or (TV) in which R 1 stands for hydrogen or it is not the R 1 group which is required in the target product.
- the R 1 group is introduced into the place of the hydrogen atom or, respectively, an R 1 group is converted into another R 1 group.
- This step can be carried out by the partial or total alkylation of the mono- or polyhydroxy-isoflavones, which alkylation can preferably be carried out by reacting with alkyl halides or substituted alkyl halides, alkyl sulfonic lactones, alkyl sulfates, olefines or epoxydes, preferably by heating the alkylating agent in a suitable solvent, e.g. ketones, dimethyl formamide or ethers containing a higher number of carbon atoms with the isoflavones to be alkylated.
- a suitable solvent e.g. ketones, dimethyl formamide or ethers containing a higher number of carbon atoms with the isoflavones to be alkylated.
- an acid binding agent such as alkali carbonate
- alkyl bromides and alkyl chlorides
- This step can be carried out by the partial or total desacylation or the partial and total desalkylation of acyloxy and polyacyloxy, alkyloxy and polyalkyloxy isoflavones.
- Acyloxy or polyacyloxy isoflavones are formed when process variant e) is carried out with di- or polyhydroxy phenyl benzyl ketones containing a hydroxy group in position 2.
- the desacylation is preferably carried out in an acidic or basic medium in the presence of a polar solvent.
- This step can also be carried out by decarboxylating isoflavone-2-carboxylic acids. Isoflavone-2- carboxylic acids are formed during process variant d) and their decarboxylation is preferably carried out by heating with or without the presence of a catalyst, such as copper dust.
- the compounds of the general formula (IB), wherein R, n, R 1 , R 2 , R 3 and R 4 are as defined for general formula (I) are prepared by the reduction of the compounds of the general formula (IA), wherein R, n, R 1 , R 2 , R 3 and R 4 are as defined for general formula (I).
- the reduction is carried out by catalytic hydrogenation or by using metal hydrides.
- a nobel metal catalyst preferably a palladium on charcoal catalyst is used and the reduction is carried out in an organic solvent, preferably in acetone.
- a complex metal hydride preferably diisobutyl aluminum hydride is used and the reduction is carried out at a low temperature (-70 °C).
- the compounds of the general formula (IC), wherein R, n, R 1 , R 2 , R 3 and R 4 are as defined for general formula (I) are prepared aby the catalytic hydrogenation of the compounds of the general formula (IB), wherein R, n, R 1 , R 2 , R 3 and R 4 are as defined for general formula (I), in the presence of a noble metal or nickel catalyst.
- the reduction is preferably carried out in a polar solvent, preferably acetic acid or ethyl acetate.
- R 1 stands for alkyl substituted by carboxy
- the hydrolysis is preferably carried out in an acidic medium, preferably with lower organic acids in the presence of a strong acid catalyst.
- the compounds of the general formula (IA) containing a methyl group in position 6 are prepared by the reduction of halomethyl isoflavones obtained from the compounds of the general formula (IA) containing a hydrogen atom in position by halomethylation.
- the reduction is carried out preferably in the presence of metals, preferably zinc.
- the compounds of the general formula (I) containing an alkoxy or hydroxymethyl group in position 6 are prepared either by replacing the halo atom of the halomethyl isoflavones prepared as described above with an alkoxy group by the aid of alcohols or by replacing said halo atom with an 0-acetyl group by the aid of sodium acetate and by subsequently converting the acetoxy group into an OH group.
- Ipriflavone (7-Isopropoxy-isoflavone) is able to inhibit bone resorption either in vitro or in vivo (Notoya, K. et al. Inhibitory effect of Ipriflavone on pit formation in mouse unfractionated bone cells, Calcif. Tissue Int. 51, (Supl. 1) 53-56 (1992); Notoya, K. et al. Inhibitory effect of Ipriflavone on osteoclast-mediated bone resorption and new osteoclast formation in long-term cultures of mouse unfractionated bone cells, Calcif Tissue Int. 50, 314-319 (1992).
- Ipriflavone also could increase the mineralization of the extracellular matrix of human bone cell cultures (Ref. Ecsedi, G.G. Model for in vitro investigation of bone mineralization, Agents and Actions 41, 84-85 (1994.)
- the compounds of the general formula (I) may be utilized in the therapy in the form of preparations containing the active ingredient together with inert, non-toxic, pharmaceutically acceptable solid or liquid diluents or carriers.
- the preparations can contain biologically active known substances such as vitamins, amino acids, choline chloride, salts of mineral acids, trace elements etc.
- talc, gelatine, calcium carbonate, magnesium stearate, starch, water, polyalkylene glycols etc. may be used.
- the compositions may be formulated as solid (e.g. tablets, dragees, capsules, suppositories etc.) or liquid (e.g. solution, suspension or emulsion) preparations.
- 7-(l-ethoxycarbonyl-l-decyloxy)-isoflavone FL 279), m.p.: 97-99 °C are prepared in a similar way from 7-hydroxy-isoflavone and the corresponding alkyl halide or substituted alkyl halide.
- 7-(3-methyl-l-butyloxy)-isoflavone FL 191), m.p.: 107-108 °C, is prepared from 7-hydroxy-3',4'-dimethoxy-isoflavone by using 3-methyl-l-butylbromid.
- a mixture of 16 g of 6-n-hexyl-7-hydroxy-isoflavone, 14 ml of isopropylbromide and 70 ml of dimethylformamide are stirred for 4 hours at a temperature of 90 °C in the presence of 16 g of potassium carbonate.
- reaction mixture is poured into 500 ml of water, the product is separated, then recrystallized from 80% aqueous methanol. 15 g of 6-n-hexyl-7-(l-methylethoxy)- -isoflavone are obtained, m.p. 37-39 °C.
- 6-n-hexyl-7-ethoxy-isoflavone FL 319, m.p.: 57-59 °C, and 6-n-hexyl-7-
- 7-ethoxy-5-methyl-isoflavan-4-one (FL 299), m.p.: 97-98 °C, is prepared in a similar way from 7-ethoxy-5-methyl-isoflavone.
- 7-cyclohexyl-isoflavan-4-one (FL 312), m.p.: 119-120 °C, is prepared from 7-(l-cyclohex-2-enyloxy)-isoflavone (FL 286) by hydrogenation until a hydrogen ptake of 2.2 equimolar amount.
- 7-cyclohexyl-isoflavane m.p.: 90-92 °C
- 7-(l- -cyclohex-2-enyloxy)-isoflavone is prepared from 7-(l- -cyclohex-2-enyloxy)-isoflavone by hydrogenation until a hydrogen uptake of 4 equimolar amount.
- Example 9 36.2 g of 2-hydroxy-4-(3-phenoxy-l-propyloxy)-phenylbenzyl-ketone, 22 g of ethyl orthofo ⁇ niate and 5 g of morpholine are boiled in 200 ml of dimethyl formamide for 8 hours. The ethanol formed during the reaction is removed through a fractionating attachment, then a great part of the solvent is evaporated in vacuo and the residue is diluted with diluted aqueous hydrochloric acid. The raw product is filtered off and recrystallized from acetone to obtain 32 g of 7-(3-phenoxy-l-propyloxy)-isoflavone (FL 230), m.p.: 123-125 °C.
- Example 13 2.0 g of 7-(carbethoxymethoxy)-isoflavone are dissolved in 10 ml of diethylamino ethanol, 2.0 g of potassium carbonate are added to the solution and the mixture is boiled for 5 hours under stirring, then poured into a mixture of ice and 2% hydrochloric acid. The product is separated by suction and recrystallized from a mixture of methanol and acetone. 7-(N,N-chethyla ⁇ unoethoxy- -carbonylmethoxy)-isoflavone (FL 105) is obtained in an amount of 1.5 g, m.p.: 227-228 °C.
- 8-acetoxymethyl-7-(2-propyloxy)-isoflavone (FL 521), m.p.: 107-109 °C, is prepared from 8-chloromethyl-7-(2-propyloxy)-isoflavone in a similar way.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94921776A EP0710234A1 (en) | 1993-07-20 | 1994-07-19 | Isoflavone derivatives |
AU72367/94A AU7236794A (en) | 1993-07-20 | 1994-07-19 | Isoflavone derivatives |
KR1019960700364A KR960703888A (en) | 1993-07-20 | 1996-01-19 | Isoflavone derivatives (ISOFLAVONE DERIVATIVES) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU9302083A HUT68558A (en) | 1993-07-20 | 1993-07-20 | Method for preparing isoflavon derivatives |
HU2083/93 | 1993-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995003293A1 true WO1995003293A1 (en) | 1995-02-02 |
Family
ID=10983803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU1994/000028 WO1995003293A1 (en) | 1993-07-20 | 1994-07-19 | Isoflavone derivatives |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0710234A1 (en) |
KR (1) | KR960703888A (en) |
CN (1) | CN1129445A (en) |
AU (1) | AU7236794A (en) |
CA (2) | CA2167597A1 (en) |
HU (1) | HUT68558A (en) |
WO (1) | WO1995003293A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998029403A1 (en) * | 1997-01-03 | 1998-07-09 | Chiesi Farmaceutici S.P.A. | Isoflavone derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
WO1999065893A1 (en) * | 1998-06-13 | 1999-12-23 | C & C Research Laboratories | Novel benzopyran or thiobenzopyran derivatives |
US6087366A (en) * | 1996-03-07 | 2000-07-11 | The Trustees Of Columbia University In The City Of New York | Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death |
EP1153020A1 (en) * | 1999-02-15 | 2001-11-14 | Novogen Research Pty. Ltd. | Production of isoflavone derivatives |
WO2002017909A1 (en) * | 2000-08-14 | 2002-03-07 | Korea Institute Of Oriental Medicine | A therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives |
WO2004014886A1 (en) * | 2002-08-07 | 2004-02-19 | University Of Mississippi | Antigiardial agents and use thereof |
WO2005121116A1 (en) * | 2004-06-08 | 2005-12-22 | Novartis Ag | Chromone derivatives useful as vanilloid antagonists |
US7033621B1 (en) | 1997-04-28 | 2006-04-25 | Novogen, Inc. | Isoflavone compositions produced from legumes |
US7312344B2 (en) | 2001-03-08 | 2007-12-25 | Novogen Research Pty Limited | Dimeric isoflavones |
US7488494B2 (en) | 1999-09-06 | 2009-02-10 | Novogen Research Pty Ltd. | Compositions and therapeutic methods involving isoflavones and analogues thereof |
JP2009536610A (en) * | 2006-02-28 | 2009-10-15 | カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ | Pharmaceutical composition for the prevention / treatment of bone disease and preparation method thereof |
US7618998B2 (en) | 2008-02-26 | 2009-11-17 | Kaosiung Medical University | Isoflavone derivatives and pharmaceutical compositions comprising the same |
US7960399B2 (en) | 2004-06-08 | 2011-06-14 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102964322A (en) * | 2012-12-12 | 2013-03-13 | 中国药科大学 | Isoflavone or flavonoid aliphatic ether derivates, preparation method and medical application thereof |
CN108264506B (en) * | 2018-01-17 | 2021-01-26 | 中国药科大学 | Isoflavone derivative, preparation method and medical application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0136569A2 (en) * | 1983-09-05 | 1985-04-10 | Takeda Chemical Industries, Ltd. | Isoflavone derivatives, their production and use |
WO1991015483A1 (en) * | 1990-04-06 | 1991-10-17 | Chinoin Gyógyszer És Vegyészeti Termékek Gyára Rt | An improved process for the preparation of substituted isoflavone derivatives |
-
1993
- 1993-07-20 HU HU9302083A patent/HUT68558A/en unknown
-
1994
- 1994-07-18 CA CA002167597A patent/CA2167597A1/en not_active Abandoned
- 1994-07-19 WO PCT/HU1994/000028 patent/WO1995003293A1/en not_active Application Discontinuation
- 1994-07-19 AU AU72367/94A patent/AU7236794A/en not_active Abandoned
- 1994-07-19 CA CA002167714A patent/CA2167714A1/en not_active Abandoned
- 1994-07-19 CN CN94193107A patent/CN1129445A/en active Pending
- 1994-07-19 EP EP94921776A patent/EP0710234A1/en not_active Withdrawn
-
1996
- 1996-01-19 KR KR1019960700364A patent/KR960703888A/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0136569A2 (en) * | 1983-09-05 | 1985-04-10 | Takeda Chemical Industries, Ltd. | Isoflavone derivatives, their production and use |
WO1991015483A1 (en) * | 1990-04-06 | 1991-10-17 | Chinoin Gyógyszer És Vegyészeti Termékek Gyára Rt | An improved process for the preparation of substituted isoflavone derivatives |
Non-Patent Citations (3)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 104, No. 17, issued 28 April 1986, (Columbus, Ohio, USA), MATSUDA, Y. et al.: "Isoflavone derivatives", page 548, column 2, abstract no. 147 153b; & JP,A,60 199 396, 08-10-95. * |
CHEMICAL ABSTRACTS, Vol. 108. No. 1, issued 04 January 1988, (Columbus, Ohio, USA), WATANABE, S. et al.: "Use of isoflavone derivatives as immunosuppressants", page 53, column 2, abstract no. 622c; & JP,A,62 106 016, 16-05-87. * |
CHEMICAL ABSTRACTS, Vol. 87, No. 3, issued 18 July 1977, (Columbus, Ohio, USA), NORO, T. et al.: "Synthesis of isoflavone derivatives. II. Synthesis of 6-hydroxy-2'-methoxy-5'-nitroisoflavone", page 623, column 2, abstract no. 22 970q; & YAKUGAKU ZASSHI 1977, 97 (2), 215-17. * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087366A (en) * | 1996-03-07 | 2000-07-11 | The Trustees Of Columbia University In The City Of New York | Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death |
WO1998029403A1 (en) * | 1997-01-03 | 1998-07-09 | Chiesi Farmaceutici S.P.A. | Isoflavone derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
US7033621B1 (en) | 1997-04-28 | 2006-04-25 | Novogen, Inc. | Isoflavone compositions produced from legumes |
US6645951B1 (en) | 1998-06-13 | 2003-11-11 | Chugai Seiyaku Kabushiki Kaisha | Benzopyran or thiobenzopyran derivatives |
WO1999065893A1 (en) * | 1998-06-13 | 1999-12-23 | C & C Research Laboratories | Novel benzopyran or thiobenzopyran derivatives |
US7074819B2 (en) | 1998-06-13 | 2006-07-11 | Chugai Seiyaku Kabushiki Kaisha | Benzopyran or thiobenzopyran derivatives |
EP1153020A4 (en) * | 1999-02-15 | 2002-08-21 | Novogen Res Pty Ltd | Production of isoflavone derivatives |
EP1153020A1 (en) * | 1999-02-15 | 2001-11-14 | Novogen Research Pty. Ltd. | Production of isoflavone derivatives |
JP2002537295A (en) * | 1999-02-15 | 2002-11-05 | ノボゲン リサーチ ピーティーワイ リミテッド | Method for producing isoflavone derivative |
US7488494B2 (en) | 1999-09-06 | 2009-02-10 | Novogen Research Pty Ltd. | Compositions and therapeutic methods involving isoflavones and analogues thereof |
WO2002017909A1 (en) * | 2000-08-14 | 2002-03-07 | Korea Institute Of Oriental Medicine | A therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives |
US7312344B2 (en) | 2001-03-08 | 2007-12-25 | Novogen Research Pty Limited | Dimeric isoflavones |
US7468445B2 (en) | 2002-08-07 | 2008-12-23 | University Of Mississippi | Antigiardial agents and use thereof |
WO2004014886A1 (en) * | 2002-08-07 | 2004-02-19 | University Of Mississippi | Antigiardial agents and use thereof |
KR100903713B1 (en) * | 2004-06-08 | 2009-06-19 | 노파르티스 아게 | Chromone Derivatives Useful as Vanilloid Antagonists |
JP2008501762A (en) * | 2004-06-08 | 2008-01-24 | ノバルティス アクチエンゲゼルシャフト | Chromone derivatives useful as vanilloid antagonists |
WO2005121116A1 (en) * | 2004-06-08 | 2005-12-22 | Novartis Ag | Chromone derivatives useful as vanilloid antagonists |
US7960399B2 (en) | 2004-06-08 | 2011-06-14 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
US8211902B2 (en) | 2004-06-08 | 2012-07-03 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
US8809528B2 (en) | 2004-06-08 | 2014-08-19 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
US9102653B2 (en) | 2004-06-08 | 2015-08-11 | Novartis Ag | Substituted quinazolinones as vanilloid antagonists |
JP2009536610A (en) * | 2006-02-28 | 2009-10-15 | カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ | Pharmaceutical composition for the prevention / treatment of bone disease and preparation method thereof |
US7618998B2 (en) | 2008-02-26 | 2009-11-17 | Kaosiung Medical University | Isoflavone derivatives and pharmaceutical compositions comprising the same |
Also Published As
Publication number | Publication date |
---|---|
CN1129445A (en) | 1996-08-21 |
EP0710234A1 (en) | 1996-05-08 |
AU7236794A (en) | 1995-02-20 |
HUT68558A (en) | 1995-06-28 |
CA2167597A1 (en) | 1995-02-02 |
HU9302083D0 (en) | 1993-10-28 |
CA2167714A1 (en) | 1995-02-02 |
KR960703888A (en) | 1996-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0710234A1 (en) | Isoflavone derivatives | |
CA1286299C (en) | 3,4-dihydrobenzopyran derivatives and medicinal uses thereof | |
RU1836344C (en) | Method for obtaining pteridine-4(3h) or their pharmaceutically acceptable salts with alkali metals | |
US4621089A (en) | Pyrazolopyridine derivatives and their use in treating inflammation and allergic conditions | |
AU2005251920A1 (en) | Chromone derivatives useful as vanilloid antagonists | |
PL119501B1 (en) | Process for manufacturing novel,condensed pyrimidine derivatives pirimidina | |
Agui et al. | Studies on quinoline derivatives and related compounds. 1. A new synthesis of 1‐alkyl‐1, 4‐dihydro‐4‐oxo‐3‐quinolinecarboxylic acids | |
US4705782A (en) | Indene and naphthalene derivatives | |
SU634673A3 (en) | Method of obtaining imidazo-/4,5-b/ pyridines or salts thereof | |
EP0055068B1 (en) | Quinolone derivatives and their use as pharmaceuticals | |
EP0350990A1 (en) | Pyridazinone derivatives | |
CN104804003A (en) | Synthesis technology of 5-aryl-1H-pyrazolopyridine[4,3-d]pyrimidine-7(6H)-ketone | |
CA2391654A1 (en) | Aryloxy propanolamines for improving livestock production | |
SU1579459A3 (en) | Method of obtaining derivatives of 1-methylaminoquinolinecarboxylic acid or their salts connecting pharmaceutically acceptable acids | |
FI71733B (en) | FREQUENCY REQUIREMENT FOR PHARMACEUTICAL ACTIVATION 3,6-SUBSTITUTE-2-VINYL CHROMONER | |
PL142254B1 (en) | Process for preparing novel derivatives of ortho-condensed pyrrole | |
CS240967B2 (en) | Preparation method of carbazic acid derivatives | |
US3449403A (en) | Novel acrylates | |
PL124296B1 (en) | Process for preparing novel derivatives of aurone | |
EP3562806A1 (en) | Methods for the preparation of 6-aminoisoquinoline | |
Shinde et al. | Sulfamic acid catalysed one-pot three-component condensation for the synthesis of 1, 4-dihydropyrano [2, 3-c] pyrazoles | |
CA1138868A (en) | Quinoxaline-di-n-oxide derivatives | |
Göker et al. | Synthesis and antiaggregator activity of some new derivatives of 4H-1-benzopyran-4-one | |
US4532242A (en) | Substituted triazolo[4,3-c]pyrimidines | |
US4612375A (en) | Substituted 4-hydrazino-pyrimides as intermediates for triazolo [4,3-c]pyrimidines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 94193107.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LT LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SI SK UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2167714 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994921776 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1996 586778 Country of ref document: US Date of ref document: 19960305 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1994921776 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994921776 Country of ref document: EP |